Literature DB >> 12673843

Hemostatic alterations in sickle cell disease: relationships to disease pathophysiology.

M J Stuart1, B N Setty.   

Abstract

The protean manifestations of sickle cell disease (SCD), especially, microvessel involvement in the vaso-occlusive process, is classically ascribed to the phenomena of erythrocyte sickling and enhanced red cell-endothelial adherence. Pertubations in various hemostatic systems occurs in SCD, both in steady state and during vaso-occlusion, with the intravascular generation of thrombin. The etiology(s) of thrombin generation in SCD will be described. Whether the activation of the cellular and plasmatic phases of hemostasis is causative or occurs as a result of vascular injury will be discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12673843

Source DB:  PubMed          Journal:  Pediatr Pathol Mol Med        ISSN: 1522-7952


  17 in total

1.  Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens!

Authors:  Mark T Gladwin; Gregory J Kato
Journal:  Haematologica       Date:  2008-01       Impact factor: 9.941

2.  Tissue factor-positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis.

Authors:  B N Yamaja Setty; Nigel S Key; A Koneti Rao; Suhita Gayen-Betal; Suba Krishnan; Carlton D Dampier; Marie J Stuart
Journal:  Br J Haematol       Date:  2012-02-24       Impact factor: 6.998

3.  Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events?

Authors:  Marilyn J Telen
Journal:  Blood Adv       Date:  2020-07-28

Review 4.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

5.  Computational imaging analysis of fibrin matrices with the inclusion of erythrocytes from homozygous SS blood reveals agglomerated and amorphous structures.

Authors:  Rodney D Averett; David G Norton; Natalie K Fan; Manu O Platt
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

6.  Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice.

Authors:  Paritha I Arumugam; Eric S Mullins; Shiva Kumar Shanmukhappa; Brett P Monia; Anastacia Loberg; Maureen A Shaw; Tilat Rizvi; Janaka Wansapura; Jay L Degen; Punam Malik
Journal:  Blood       Date:  2015-08-18       Impact factor: 22.113

Review 7.  Interplay between coagulation and vascular inflammation in sickle cell disease.

Authors:  Erica Sparkenbaugh; Rafal Pawlinski
Journal:  Br J Haematol       Date:  2013-04-18       Impact factor: 6.998

Review 8.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

9.  Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin.

Authors:  José Villagra; Sruti Shiva; Lori A Hunter; Roberto F Machado; Mark T Gladwin; Gregory J Kato
Journal:  Blood       Date:  2007-05-29       Impact factor: 22.113

10.  Inflammation in sickle cell disease.

Authors:  Nicola Conran; John D Belcher
Journal:  Clin Hemorheol Microcirc       Date:  2018       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.